Anna Wolska-Washer

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Radiation Therapy

Top Venues

Expert opinion on drug metabolism & toxicology

Expert review of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology (2024)
Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology (2024)
Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology 20 (4) (2024)
Anna Wolska-Washer, Pawel Robak, Magdalena Witkowska, Tadeusz Robak
Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. Expert opinion on drug metabolism & toxicology 20 (4) (2024)
Magdalena Witkowska, Agata Majchrzak, Pawel Robak, Anna Wolska-Washer, Tadeusz Robak
Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia. Expert opinion on drug metabolism & toxicology (2023)
Anna Wolska-Washer, Piotr Smolewski
Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies. Cancers 14 (15) (2022)
Anna Wolska-Washer, Tadeusz Robak
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert review of hematology 15 (3) (2022)